Canada markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
9.35-0.09 (-0.95%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.44
Open9.45
Bid9.34 x 2900
Ask9.37 x 3200
Day's Range9.31 - 9.49
52 Week Range6.25 - 13.76
Volume4,016,824
Avg. Volume8,350,087
Market Cap10.333B
Beta (5Y Monthly)1.48
PE Ratio (TTM)2,337.50
EPS (TTM)0.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov. 27, 2017
1y Target Est12.19
  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline – TEVA

    NEW YORK, NY / ACCESSWIRE / October 23, 2020 / Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited ("Teva" or the "Company") (NYSE:TEVA) and certain of its officers.

  • GlobeNewswire

    ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm – TEVA

    NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the “Class Period”), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws. To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1956.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Teva’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva's revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm when the truth became known; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1956.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.\-------------------------------Contact Information:        Laurence Rosen, Esq.         Phillip Kim, Esq.         The Rosen Law Firm, P.A.         275 Madison Avenue, 40th Floor         New York, NY 10016         Tel: (212) 686-1060         Toll Free: (866) 767-3653         Fax: (212) 202-3827         lrosen@rosenlegal.com         pkim@rosenlegal.com         cases@rosenlegal.com         www.rosenlegal.com

  • 6 Low Price-to-Book Stocks That May Prove to be Solid Bets
    Zacks

    6 Low Price-to-Book Stocks That May Prove to be Solid Bets

    When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.